Dedicated To Creating New Standards Of Care For Patients

At Cullinan Therapeutics, we take a modality-agnostic, targeted approach to discover and develop molecules with the potential to make a meaningful difference in patients’ lives.

Cullinan Therapeutics, formerly Cullinan Oncology, was founded in 2016 and is located in the science and technology hub of Cambridge, Massachusetts (in fact, our programs are named after Cambridge area codes).

Our in-house expertise and diverse backgrounds, along with our collaborative culture and deep commitment to following the science, helps advance new solutions for patients.
Image of Circles

What Makes Us Different?

At Cullinan Therapeutics, our research is anchored in a deep understanding of oncology, immunology, and translational medicine. We create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of cancer and autoimmune indications.

Cullinan Therapeutics Values Diagram

Our Company


Our Commitment to Diversity, Equity, and Inclusion

At Cullinan Therapeutics, we believe that Diversity, Equity, and Inclusion (DEI) are vital to our mission to create new standards of care for patients. We purposefully prioritized DEI early in the growth of Cullinan Therapeutics because at the heart of what we do, we aim to make transformational changes for patients, and patients from all backgrounds deserve to be represented in that effort. We acknowledge that DEI is not merely an initiative but a fundamental practice that must permeate every facet of our organization. It is with this understanding that we make the following commitments:


To build diverse teams: We endeavor to embed DEI principles into every step of our employee life cycle, ensuring that our recruiting, hiring, onboarding, development, and advancement processes are equitable and inclusive. We actively seek diversity on our teams, promote equal opportunities for all, and create a workplace that better represents the community of patients we serve.


To advance health equity: We are dedicated to ensuring that our recruitment for clinical trials is inclusive and results in participation from a diverse cross-section of patients. We strive for representation of the patients who will ultimately benefit from our medicines, and we recognize that achieving this goal requires working with our partners across the healthcare ecosystem to remove barriers to access, expand participation, and tackle the unique challenges faced by underserved communities.


To foster an inclusive culture: We will cultivate an environment where everyone can feel seen, heard, and valued. We will provide learning opportunities and support systems to enhance cultural competence and allyship within our organization and community. Furthermore, we actively seek diverse external perspectives from across the industry and academic community to enrich our scientific pursuits and challenge our ideas.


We commit to revisiting these actions regularly to enable growth and change as the company evolves and our pipeline matures. We hold ourselves accountable to creating a positive and transformative impact in the lives of our employees, for patients in need of new treatment options, and within the healthcare industry as a whole.

Building a culture of DE&I at Cullinan

Keeping DE&I at the forefront of clinical development

Innovators Creating New Standards of Care

Deep scientific expertise, creativity, and urgency drives our work.